{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T16:18:34Z","timestamp":1789402714233,"version":"build-2803163510"},"reference-count":61,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2018YFA0902802"],"award-info":[{"award-number":["2018YFA0902802"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271877"],"award-info":[{"award-number":["82271877"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071777"],"award-info":[{"award-number":["82071777"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.urolonc.2025.03.023","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T15:14:29Z","timestamp":1748099669000},"page":"473-484","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparative efficacy of adjuvant chemotherapy and immunotherapy after radical surgery for upper tract urothelial carcinoma: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"43","author":[{"given":"Yang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jincong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Rui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caipeng","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3899-1500","authenticated-orcid":false,"given":"Tao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2025.03.023_bib0001","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.eururo.2020.05.042","article-title":"European Association of Urology Guidelines on upper urinary tract urothelial carcinoma: 2020 update","volume":"79","author":"Roupr\u00eat","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0002","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00345-016-1928-x","article-title":"Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)","volume":"35","author":"Soria","year":"2017","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0003","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.eururo.2014.11.035","article-title":"A systematic review and meta-analysis of clinicopathologic factors linked to intravesical recurrence after radical nephroureterectomy to treat upper tract urothelial carcinoma","volume":"67","author":"Seisen","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0004","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eururo.2023.03.013","article-title":"European Association of Urology Guidelines on upper urinary tract urothelial carcinoma: 2023 update","volume":"84","author":"Roupr\u00eat","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0005","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.eururo.2010.06.029","article-title":"Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy","volume":"58","author":"Kaag","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0006","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","article-title":"Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Bellmunt","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0007","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.eururo.2023.06.007","article-title":"Updated overall survival by circulating tumor DNA status from the phase 3 IMvigor010 trial: adjuvant Atezolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"85","author":"Powles","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0008","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant Nivolumab versus Placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.urolonc.2025.03.023_bib0009","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.24.00340","article-title":"Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274","volume":"43","author":"Galsky","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0010","doi-asserted-by":"crossref","first-page":"LBA531","DOI":"10.1200\/JCO.2024.42.4_suppl.LBA531","article-title":"AMBASSADOR Alliance A031501: phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma (MIUC) vs observation","volume":"42","author":"Apolo","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.03.023_bib0011","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa2401726","article-title":"Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma","volume":"392","author":"Apolo","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0012","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"Bmj"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0013","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0014","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0015","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1200\/JCO.23.01659","article-title":"Improved disease-free survival with adjuvant chemotherapy after nephroureterectomy for upper tract urothelial cancer: final results of the POUT trial","volume":"42","author":"Birtle","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0016","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-74940-x","article-title":"Adjuvant chemotherapy after radical nephroureterectomy improves the survival outcome of high-risk upper tract urothelial carcinoma patients with cardiovascular comorbidity","volume":"10","author":"Luo","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0017","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","article-title":"Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial","volume":"395","author":"Birtle","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0018","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1200\/JCO.2012.45.2128","article-title":"Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial","volume":"31","author":"Shintaku","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0019","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000092930","article-title":"Adjuvant chemotherapy in the management of pT3N0M0 transitional cell carcinoma of the upper urinary tract","volume":"77","author":"Lee","year":"2006","journal-title":"Urol Int"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0020","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1442-2042.2008.02114.x","article-title":"Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma","volume":"15","author":"Soga","year":"2008","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0021","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.juro.2009.05.011","article-title":"Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration","volume":"182","author":"Hellenthal","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0022","doi-asserted-by":"crossref","first-page":"686","DOI":"10.7150\/jca.7326","article-title":"The efficacy of adjuvant chemotherapy for locally advanced upper tract urothelial cell carcinoma","volume":"4","author":"Kim","year":"2013","journal-title":"J Cancer"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0023","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.urolonc.2014.04.006","article-title":"Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: results from the Canadian Upper Tract Collaboration","volume":"32","author":"Fradet","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0024","first-page":"333","article-title":"Adjuvant radiotherapy for stage III\/IV urothelial carcinoma of the upper tract","volume":"34","author":"Jwa","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0025","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/bju.12369","article-title":"Predictors of survival in patients with disease recurrence after radical nephroureterectomy","volume":"113","author":"Kluth","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0026","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.urolonc.2013.06.015","article-title":"High rates of advanced disease, complications, and decline of renal function after radical nephroureterectomy","volume":"32","author":"Raman","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0027","doi-asserted-by":"crossref","first-page":"31.e17","DOI":"10.1016\/j.urolonc.2012.11.014","article-title":"Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: assessment of adequate renal function and influence on outcome","volume":"32","author":"Yafi","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0028","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.juro.2015.03.077","article-title":"The efficacy of postoperative adjuvant chemotherapy for patients with pT3N0M0 upper tract urothelial carcinoma","volume":"194","author":"Huang","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0029","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1590\/S1677-5538.IBJU.2015.0009","article-title":"Adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: updated results of the Seoul National University Hospital experience","volume":"41","author":"Kim","year":"2015","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0030","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4111\/kju.2015.56.1.41","article-title":"Impact of adjuvant chemotherapy in patients with upper tract urothelial carcinoma and lymphovascular invasion after radical nephroureterectomy","volume":"56","author":"Lee","year":"2015","journal-title":"Korean J Urol"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0031","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/bju.12801","article-title":"The role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma following radical nephroureterectomy: a retrospective study","volume":"116","author":"Lucca","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0032","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.juro.2014.10.022","article-title":"Impact of an adjuvant chemotherapeutic regimen on the clinical outcome in high risk patients with upper tract urothelial carcinoma: a Japanese multi-institution experience","volume":"193","author":"Shirotake","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0033","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12894-017-0305-4","article-title":"Adjuvant chemotherapy improves survival of patients with high-risk upper urinary tract urothelial carcinoma: a propensity score-matched analysis","volume":"17","author":"Fujita","year":"2017","journal-title":"BMC Urol"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0034","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3346\/jkms.2017.32.2.335","article-title":"Impact of the ASA physical status score on adjuvant chemotherapy eligibility and survival of upper tract urothelial carcinoma patients: a multicenter study","volume":"32","author":"Kang","year":"2017","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0035","doi-asserted-by":"crossref","first-page":"e1055","DOI":"10.1016\/j.clgc.2017.07.009","article-title":"Predictors for intravesical recurrence following radical nephroureterectomy for upper tract urothelial carcinoma: a national multicenter analysis","volume":"15","author":"Lee","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0036","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s00345-017-2032-6","article-title":"Efficacy of post-nephroureterectomy cisplatin-based adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: a multi-institutional retrospective study","volume":"35","author":"Nakagawa","year":"2017","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0037","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1200\/JCO.2016.69.4141","article-title":"Effectiveness of adjuvant chemotherapy after radical nephroureterectomy for locally advanced and\/or positive regional lymph node upper tract urothelial carcinoma","volume":"35","author":"Seisen","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0038","doi-asserted-by":"crossref","first-page":"e669","DOI":"10.1016\/j.clgc.2017.10.014","article-title":"Selected high-risk patients with upper tract urothelial carcinoma treated with radical nephroureterectomy for Adjuvant chemotherapy: a multi-institutional retrospective study","volume":"16","author":"Ikeda","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0039","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bju.14020","volume":"121","author":"Necchi","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0040","first-page":"1341","article-title":"Outcomes of stage II-IV upper-tract urothelial carcinoma and adjuvant chemotherapy for locally advanced cancer","volume":"17","author":"Chang","year":"2019","journal-title":"Oncol Lett"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0041","doi-asserted-by":"crossref","first-page":"6896","DOI":"10.7150\/jca.34103","article-title":"Role of Adjuvant chemotherapy in advanced stage upper urinary tract urothelial carcinoma after radical nephroureterectomy: competing risk analysis after propensity score-matching","volume":"10","author":"Kang","year":"2019","journal-title":"J Cancer"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0042","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.ijrobp.2019.03.027","article-title":"Adjuvant treatments for advanced stage, non-metastatic upper tract urothelial carcinoma: a multicenter study","volume":"104","author":"Kim","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0043","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1007\/s00432-019-03020-z","article-title":"Association between lymphovascular invasion and oncologic outcomes among upper urinary tract urothelial carcinoma patients who underwent radical nephroureterectomy","volume":"145","author":"Song","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0044","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ijsu.2019.04.013","article-title":"Impact of adjuvant chemotherapy on oncologic outcomes following radical nephroureterectomy for patients with pT3NanyM0 upper tract urothelial carcinoma: a retrospective cohort study","volume":"66","author":"Song","year":"2019","journal-title":"Int J Surg"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0045","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1007\/s00345-020-03118-x","article-title":"Adjuvant chemotherapy improves overall survival in patients with localized upper tract urothelial carcinoma harboring pathologic vascular invasion: a propensity score-matched analysis of multi-institutional cohort","volume":"38","author":"Matsunaga","year":"2020","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0046","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1007\/s00345-019-03003-2","article-title":"Differences in survival and impact of adjuvant chemotherapy in patients with variant histology of tumors of the renal pelvis","volume":"38","author":"Tully","year":"2020","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0047","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1012292","article-title":"Survival and risk factors among upper tract urothelial carcinoma patients after radical nephroureterectomy in Northeast China","volume":"12","author":"Gao","year":"2022","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.03.023_bib0048","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3390\/jpm12020226","article-title":"Clinical efficacy of adjuvant chemotherapy in advanced upper tract urothelial carcinoma (pt3-t4): real-world data from the taiwan upper tract urothelial carcinoma collaboration group","volume":"12","author":"Lin","year":"2022","journal-title":"J Pers Med"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0049","article-title":"Intravesical recurrence factors and outcome after radical nephroureterectomy for upper tract urothelial carcinoma: multivariate analysis with propensity score matching","volume":"12","author":"Zhao","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0050","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1115830","article-title":"Benefits of lymphadenectomy for upper tract urothelial carcinoma only located in the lower ureter: a bicentre retrospective cohort study","volume":"13","author":"Cui","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0051","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3233\/BLC-230041","article-title":"Impact of adjuvant gemcitabine containing chemotherapy following radical nephroureterectomy for patients with upper tract urothelial carcinoma: results from a propensity-score matched cohort study","volume":"9","author":"Hongda","year":"2023","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102069","article-title":"Effectiveness of Adjuvant chemotherapy in variant histology upper tract urothelial carcinoma following radical nephroureterectomy: stabilized inverse probability treatment weighting analysis of single center experience","volume":"22","author":"Park","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0053","first-page":"E32","article-title":"Impact of adjuvant chemotherapy for patients with locally advanced upper tract urothelial carcinoma in real-world clinical practice","volume":"18","author":"Teishima","year":"2024","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0054","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s12885-024-11919-1","article-title":"The efficacy and safety of tislelizumab combined with gemcitabine plus cisplatin in the treatment of postoperative patients with muscle-invasive upper tract urothelial carcinoma","volume":"24","author":"Zhang","year":"2024","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.urolonc.2025.03.023_bib0055","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s12094-024-03659-2","article-title":"Effectiveness and safety of adjuvant treatment of tislelizumab with or without chemotherapy in patients with high-risk upper tract urothelial carcinoma: a retrospective, real-world study","volume":"27","author":"Quan","year":"2025","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0056","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1006\/gyno.1993.1184","article-title":"Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin","volume":"50","author":"Cornelison","year":"1993","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0057","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1200\/JCO.22.02763","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"41","author":"von der Maase","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0058","doi-asserted-by":"crossref","first-page":"124","DOI":"10.5415\/apallergy.0000000000000146","article-title":"From tumor to tolerance: a comprehensive review of immune checkpoint inhibitors and immune-related adverse events","volume":"14","author":"Sutanto","year":"2024","journal-title":"Asia Pac Allergy"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0059","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1200\/JCO.21.01485","article-title":"Neoadjuvant Atezolizumab with Gemcitabine and Cisplatin in patients with muscle-invasive bladder cancer: a multicenter, single-arm, phase II trial","volume":"40","author":"Funt","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0060","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1200\/JCO.2020.38.15_suppl.5047","article-title":"Phase ib\/II neoadjuvant (N-) pembrolizumab (P) and chemotherapy for locally advanced urothelial cancer (laUC): final results from the cisplatin (C)- eligible cohort of HCRN GU14-188","volume":"38","author":"Hoimes","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.03.023_bib0061","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216167","article-title":"Improvement strategy for immune checkpoint blockade: a focus on the combination with immunogenic cell death inducers","volume":"562","author":"Shi","year":"2023","journal-title":"Cancer Lett"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925001255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925001255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T11:36:03Z","timestamp":1754912163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925001255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":61,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1078143925001255"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.03.023","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative efficacy of adjuvant chemotherapy and immunotherapy after radical surgery for upper tract urothelial carcinoma: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.03.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}